adrc@med.usc.edu

Phenserine Study

Examines the effects of a novel therapeutic (phenserine tartrate) in the treatment of Alzheimer’s disease.

More Details About the Study

Why should I participate in this study?

Study participants will help broaden our understanding of the potential therapeutic role of phenserine tartrate in degenerative cognitive impairment. They will also be compensated for their time.

Am I eligible to participate?

We are enrolling individuals who are:

70-82 years old
Diagnosed with mild cognitive impairment OR Alzheimer’s disease
Must have study partner willing to participate as well

Share this study

More studies

ADNI4

The next phase of Alzheimer’s Disease Neuroimaging Initiative (ADNI) research, ADNI4 is now recruiting participants with or without memory issues to help us continue investigating important questions concerning early detection of mild cognitive impairment and Alzheimer’s Disease.

Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD)

Assesses therapeutic potential of escitalopram in managing certain behavioral symptoms of Alzheimer’s disease.

Cerebral Small Vessel Disease Study (VCID)

Research study involving new techniques of identifying the earliest physical changes connected to an increased risk of stroke and cognitive impairment.